India Oncology Clinical Trials Market Report 2022 to 2030

India Oncology Clinical Trials Market Analysis

$ 3999

India's oncology clinical trials market is projected to grow from $230.1 Mn in 2022 to $441.8 Mn by 2030, registering a CAGR of 8.5% during the forecast period of 2022-30. The market will be driven by the rising prevalence of Oncological disorders, the availability of a large patient pool with various genetic profiles, and low-cost clinical trials. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cadila Healthcare Ltd. & Cipla Ltd.

ID: IN10INCT006 CATEGORY: Clinical Trials GEOGRAPHY: India AUTHOR: Vidhi Upadhyay

Buy Now

India Oncology Clinical Trials Market Executive Summary

The India oncology clinical trials market is projected to grow from $230.1 Mn in 2022 to $441.8 Mn by 2030, registering a CAGR of 8.5% during the forecast period of 2022-30. According to the Indian Council of Medical Research's (ICMR) National Cancer Registry Project, the anticipated incidence of cancer cases in India across different states and union territories in 2020 was 1.39 Mn rising to 1.42 Mn in 2021 and 1.46 Mn in 2022 and are expected to double by 2040. The five most frequent malignancies in India are lung, oral, cervical, breast, and stomach cancer. In India, one in every nine persons will acquire cancer over their lifetime. Lung and breast cancers were the most common cancer locations in men and women, respectively.

Clinical trials in India are still 60% cheaper than in the United States. India has 1,762 world-class hospitals as trial locations and 4,216 ICH-GCP-qualified investigators. In recent years, India's oncology clinical trials industry has grown significantly. With a big and diversified patient population, a well-established healthcare system, and relatively inexpensive rates when compared to developed countries, India has become an appealing venue for pharmaceutical firms seeking to perform oncology clinical trials.

Various hospitals and research institutes in India are involved in oncology clinical trials for example;

Kidwai Memorial Institute of Oncology, Bengaluru
Tata Memorial Centre, Mumbai
All India Institute of Medical Sciences (AIIMS), New Delhi
Fortis Memorial Research Institute
Apollo Hospitals
Rajiv Gandhi Cancer Institute and Research Centre, New Delhi

In November 2022, An ultra-low dosage of the immunotherapy medicine nivolumab (Opdivo) was shown to help persons with advanced head and neck cancer live much longer lives in Indian research. Additionally, since the dosage is 6% of what is generally used in the United States and Europe, it may be less expensive.

india oncology clinical trials market analysis

Market Dynamics

Market Growth Drivers

The Network of Oncology Clinical Trials in India (NOCI) is a National Biopharma Mission programme backed by the Biotechnology Industry Research Assistance Council (BIRAC). This project's goal is to improve the capacity to undertake industry-sponsored clinical studies of cancer medicines and biosimilars with the ultimate goal to boost and accelerate the indigenous development of novel anti-cancer medicines.

The number of clinical trials undertaken in India has increased significantly, notably in oncology. The availability of a large patient pool with various genetic profiles is crucial for assessing the safety and effectiveness of novel cancer medicines. Moreover, India has a well-established medical infrastructure, including a robust network of hospitals and research institutes, allowing for easy recruitment and supervision of clinical trial participants. Another reason driving the rise of cancer clinical trials in India is the availability of trained clinical research workers at a cheaper cost than in other nations. As a result, India has become an appealing site for sponsors seeking to conduct cost-effective clinical studies without sacrificing quality.

Market Restraints

There are other constraints to consider as well. Regulatory compliance is one of the most significant barriers to the expansion of cancer clinical trials in India. Regulatory authorities have expressed concerns in recent years regarding the safety of clinical trial participants and the ethical standards of certain trials. This has led to greater scrutiny and more severe rules, which may lead to delays in research approvals and higher expenses.

Another issue confronting cancer clinical trials in India is a lack of clinical trial knowledge and comprehension among patients and healthcare professionals. This may make it more challenging to recruit qualified volunteers and have an influence on the quality of data collected by the research.

Competitive Landscape

Key Players

Pfizer Inc.
Novartis International AG
AstraZeneca
Roche Holding AG
Bristol-Myers Squibb Company
Merck & Co., Inc.
Johnson & Johnson
Sun Pharmaceutical Industries Ltd. (IND)
Cadila Healthcare Ltd. (IND)
Cipla Ltd. (IND)
Lupin Ltd. (IND)
Glenmark Pharmaceuticals Ltd. (IND)
Biocon Ltd. (IND)

Notable Deals

January 2023, Sun Pharmaceutical Industries Ltd. announced the introduction of Palbociclib, a breakthrough anti-cancer medicine, in India by one of its wholly-owned subsidiaries for patients with advanced breast cancer
In November 2022, Cipla introduced an injectable for advanced prostate cancer in the United States
August 2022, Lupin received FDA authorisation to commercialise a generic cancer treatment medication
In January 2022, Cadila Pharmaceuticals introduced trastuzumab under the trade name Tarzed. It is a humanised monoclonal antibody that is suggested for HER2-positive early-stage breast cancer and metastatic breast cancer

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Oncology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.